Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales

BACKGROUND: Neonatal sepsis is a serious and frequently lethal infection, often complicated by antimicrobial resistance (including ESBLs) in low- and middle-income countries (LMICs). Flomoxef is an off-patent oxacephem β-lactam with stability against non-AmpC ESBLs, with potential for utility in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Darlow, Christopher A, Hope, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864998/
https://www.ncbi.nlm.nih.gov/pubmed/34969066
http://dx.doi.org/10.1093/jac/dkab468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864998/
https://www.ncbi.nlm.nih.gov/pubmed/34969066
http://dx.doi.org/10.1093/jac/dkab468

Ejemplares similares